William Sheridan
About William Sheridan
William Sheridan, Chief Development Officer and Interim Chief Medical Officer at BioCryst, has extensive experience in medical affairs and clinical development, previously contributing significantly at Amgen.
Company and Title at BioCryst
William Sheridan currently serves as the Chief Development Officer and Interim Chief Medical Officer at BioCryst Pharmaceuticals. He joined the company in July 2008. In his roles, he oversees the development and implementation of key medical strategies. His position involves significant leadership responsibilities, guiding the company's clinical development and medical affairs efforts.
Experience and Tenure at Amgen
Before joining BioCryst, William Sheridan spent 15 years at Amgen, a leading biotechnology company. During his tenure, he organized and led the Medical Affairs functions across the United States and Europe. He also played a key role in launching several important compounds. Additionally, he was responsible for organizing the Global Health Economics and Outcomes Research function. He supervised product development team leaders and directed multiple clinical development-phase product development teams.
Education and Medical Qualifications
William Sheridan earned his M.B. B.S. degree, which is equivalent to an M.D., from the University of Melbourne in Victoria, Australia. He is a board-certified fellow of the Royal Australasian College of Physicians, specializing in medical oncology. William Sheridan is also a fellow of the American College of Physicians, reflecting his recognized expertise and professional standing in the medical community.
Clinical and Research Contributions
With extensive experience in the biotech sector, William Sheridan has made significant contributions to clinical research and product development. At Amgen, he guided key projects from the development phase to successful market launches. His involvement in organizing the Global Health Economics and Outcomes Research function underscores his capability in aligning clinical outcomes with economic perspectives, enhancing the overall healthcare impact of the products he has worked on.
Roles and Responsibilities at BioCryst
In his dual roles at BioCryst, William Sheridan is responsible for the strategic direction and daily operations of the development and medical affairs departments. As Chief Development Officer, he ensures that the company's product pipeline advances efficiently through various stages of clinical trials. As Interim Chief Medical Officer, he oversees medical strategies and patient safety, ensuring alignment with regulatory standards and clinical best practices.